Annals of internal medicine
-
Comment
In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk.
Loftus EV Jr, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med. 2023;388:1966-1980. 37224198.
-
Review
Factors Associated With Circulating Sex Hormones in Men : Individual Participant Data Meta-analyses.
Various factors modulate circulating testosterone in men, affecting interpretation of testosterone measurements. ⋯ Medical Research Future Fund, Government of Western Australia, and Lawley Pharmaceuticals. (PROSPERO: CRD42019139668).
-
Comment Randomized Controlled Trial
In adults with cancer and VTE, DOACs were noninferior to LMWH for recurrent, nonfatal VTE at 6 mo.
Schrag D, Uno H, Rosovsky R, et al; CANVAS Investigators. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA. 2023;329:1924-1933. 37266947.
-
Butler J, Packer M, Siddiqi TJ, et al. Efficacy of empagliflozin in patients with heart failure across kidney risk categories. J Am Coll Cardiol. 2023;81:1902-1914. 37164523.